×

Research and Markets: Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis

DUBLIN, Nov 12, 2010 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/36caf0/triple_analysis_m) has announced the addition of the "Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis.

Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report: Part I: Melanoma The melanoma report part comprises defined and up to date development strategies for 124 melanoma drugs within the portfolio of 95 investigators, from Preclinical to Marketed. This report part extensively analyses 118 identified targets of melanoma drugs, organized into 94 drug target strategies, and assesses them in melanoma.

This part is based on the following publication: Currently Druggable in Melanoma: A Drug Target Competitive Analysis Part II: Prostate Cancer The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication: A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market Part III: Angiogenesis The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

This part is based on the following publication: Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by: Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities Supporting development of integrative molecule, pathway and disease area strategies Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered: Part I: Melanoma 5 How to Use this Report 12 Drug Target Profiles of Melanoma Drugs (118 Drug Targets) 70- 14 The Progression and Maturity of Melanoma Targets (94 Drug Target Strategies and 124 Drugs) 218- 15 Targets by R&D Approach in Melanoma (7 Different Compound Strategies) 234- 16 Melanoma Targets by Companies (95 Investigators) 252- 18 Drug Index 19 Company Index Figures: Includes 6 Figures Tables: Includes 46 Tables Part II: Prostate Cancer 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32- 7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384- 8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486- 11 Drug Index 12 Company Index Figures: Includes 6 Figures Tables: Includes 257 Tables Part III: Angiogenesis 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39- 7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367- 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438- 9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644- 10 Disclaimer 11 Drug Index 12 Company Index Figures: Includes 7 Figures Tables: Includes 300 Tables For more information visit http://www.researchandmarkets.com/research/36caf0/triple_analysis_m SOURCE: Research and Markets CONTACT: Research and Markets Laura Wood, Senior Manager, press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2010 -0- KEYWORD: Europe

North America INDUSTRY KEYWORD: Health

Pharmaceutical

General Health